Dorian Yarih García-Ortega , Miguel Ángel Clara-Altamirano , Daniel Montaño-Gómez , Héctor Martínez-Said , Claudia Haydee Sarai Caro-Sánchez , Mario Cuéllar-Hubbe
{"title":"Sinovitis villonodular de la articulación coxofemoral, presentación atípica: reporte de caso y revisión de la literatura","authors":"Dorian Yarih García-Ortega , Miguel Ángel Clara-Altamirano , Daniel Montaño-Gómez , Héctor Martínez-Said , Claudia Haydee Sarai Caro-Sánchez , Mario Cuéllar-Hubbe","doi":"10.1016/j.gamo.2016.09.011","DOIUrl":"https://doi.org/10.1016/j.gamo.2016.09.011","url":null,"abstract":"<div><h3>Introduction</h3><p>Pigmented villonodular synovitis is an uncommon clinical condition, with a higher incidence in women of 3:1, and an age of presentation between 20-40 years old. The hip is an uncommon site, being involved in only 15% of all cases.</p></div><div><h3>Case report</h3><p>A 47 year-old male 47 years with a history of 10 years onset, characterised by limited range of movement, pain associated with increased volume and shortening of pelvic limb. Imaging studies showed destruction of hip joint and extension to the pelvis. The histopathology reported pigmented villonodular synovitis. Treatment included a left outer hemipelvectomy.</p></div><div><h3>Conclusions</h3><p>The presentation of a diffuse pigmented villonodular synovitis hip has a low incidence and its locally aggressive behaviour makes it necessary to perform differential diagnoses to include malignancies. The standard treatment is surgical.</p></div>","PeriodicalId":41581,"journal":{"name":"Gaceta Mexicana de Oncologia","volume":"15 6","pages":"Pages 371-374"},"PeriodicalIF":0.1,"publicationDate":"2016-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.gamo.2016.09.011","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136918499","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pedro de Jesús Sobrevilla Calvo , Nora Sobrevilla Moreno , Francisco Javier Ochoa Carrillo
{"title":"Neutropenia inducida por quimioterapia: el punto de vista del oncólogo","authors":"Pedro de Jesús Sobrevilla Calvo , Nora Sobrevilla Moreno , Francisco Javier Ochoa Carrillo","doi":"10.1016/j.gamo.2016.08.006","DOIUrl":"https://doi.org/10.1016/j.gamo.2016.08.006","url":null,"abstract":"<div><p>Chemotherapy-induced neutropenia is a frequent and serious complication of the oncological treatment. One of its consequences is the interruption of the cytotoxic treatment, which affects the patient response and quality of life, as well as increasing the cost of medical care. Management of chemotherapy-induced neutropenia must include preventive and therapeutic strategies, which the oncologist must take into account when considering the potential myelosuppressive agent and to implement the appropriate treatment approaches. Granulocyte colony stimulating factors are the cornerstone for the management of this complication and have become quite effective treatment tools.</p></div>","PeriodicalId":41581,"journal":{"name":"Gaceta Mexicana de Oncologia","volume":"15 6","pages":"Pages 344-349"},"PeriodicalIF":0.1,"publicationDate":"2016-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.gamo.2016.08.006","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136918478","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jesús Livio Jiménez-Santos, José Luis González-Vela, Gerardo Villarreal, Juan Francisco González-Guerrero
{"title":"Docetaxel en cáncer de mama metastásico multitratado","authors":"Jesús Livio Jiménez-Santos, José Luis González-Vela, Gerardo Villarreal, Juan Francisco González-Guerrero","doi":"10.1016/j.gamo.2016.08.005","DOIUrl":"https://doi.org/10.1016/j.gamo.2016.08.005","url":null,"abstract":"<div><h3>Introduction</h3><p>Docetaxel every 15 days could be an option for patients with progression after already having therapy with three treatment lines, since it may be safe and effective in advanced, elderly, and fragile patients.</p></div><div><h3>Objective</h3><p>To demonstrate the efficacy and safety of docetaxel in patients with metastatic cancer and a background of chemotherapy treatment with paclitaxel or docetaxel as adjuvants, as well as having presented with disease progression in a period of less than a year.</p></div><div><h3>Material and methods</h3><p>Women aged between 21 and 89 years old treated in the <em>Centro Universitario Contra el Cáncer</em> of the UANL in Monterrey NL, México, from 2013 to 2015. Variables considered were: age, menopausal status, hormone receptors status, over expression of HER2 neu, location of metastatic sites, performance status 0-3, and comorbidities.</p></div><div><h3>Results</h3><p>Only 16 patients were evaluable among the 19 patients meeting the inclusion criteria. Nine patients (35%) had a partial response, and seven patients had stable disease status. Median progression free survival was 5.2 months; 95% CI; 3.1-10.3 months.</p></div><div><h3>Conclusions</h3><p>Patients with relapsing disease within 2 years after previous therapy with taxanes benefited most, since they may receive taxanes again. The most important predictors for docetaxel efficacy were visceral metastases, and the duration of the disease free interval.</p></div>","PeriodicalId":41581,"journal":{"name":"Gaceta Mexicana de Oncologia","volume":"15 6","pages":"Pages 332-335"},"PeriodicalIF":0.1,"publicationDate":"2016-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.gamo.2016.08.005","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136918480","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Competencia para cuidar en el hogar y sobrecarga en el cuidador del niño con cáncer","authors":"Sonia Carreño Moreno, Mauricio Arias Rojas","doi":"10.1016/j.gamo.2016.09.009","DOIUrl":"https://doi.org/10.1016/j.gamo.2016.09.009","url":null,"abstract":"<div><p>Family caregivers of children with cancer face a new role in caring at home, which requires them to be competent. The complexity of child care can generate burden.</p></div><div><h3>Objective</h3><p>Describe the level of homecare competency and the burden in family caregivers of children with cancer, and establish whether there is a relationship between the 2 variables.</p></div><div><h3>Materials and methods</h3><p>A descriptive, correlational and cross-sectional study was conducted using questionnaires to assess sociodemographic data (GCPF-UN-D), homecare competency (CUIDAR-GCPC-UN-CPC), and burden in the caregiver (Zarit burden interview). The sample consisted of 118 family caregivers of children with cancer. Descriptive statistics and Spearman Rho coefficient were used. Informed consent was given.</p></div><div><h3>Results</h3><p>Average levels of homecare competency and absence of burden were found in the majority of caregivers. There were weak correlations (<em>P</em> <!--><<!--> <!-->.05) between the homecare competency-dimension of anticipation and caregiver burden.</p></div><div><h3>Conclusion</h3><p>The family caregiver of children with cancer needs to be prepared to provide care at home. It is advisable to conduct studies to expand what is known of caregiver burden of children with cancer and their measurement.</p></div>","PeriodicalId":41581,"journal":{"name":"Gaceta Mexicana de Oncologia","volume":"15 6","pages":"Pages 336-343"},"PeriodicalIF":0.1,"publicationDate":"2016-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.gamo.2016.09.009","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136918482","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Michelle Lilly Rojas Arellano , Víctor Hugo Carmona Ornelas , Mauro García Bahena , Sergio Bruno Muñoz Cortés , Ángel Augusto Pérez-Calatayud
{"title":"Coriocarcinoma durante la perimenopausia: reporte de un caso","authors":"Michelle Lilly Rojas Arellano , Víctor Hugo Carmona Ornelas , Mauro García Bahena , Sergio Bruno Muñoz Cortés , Ángel Augusto Pérez-Calatayud","doi":"10.1016/j.gamo.2016.09.010","DOIUrl":"https://doi.org/10.1016/j.gamo.2016.09.010","url":null,"abstract":"<div><h3>Introduction</h3><p>There are few cases reported in the literature on gestational trophoblastic disease in postmenopausal women, and there are even fewer reports of choriocarcinoma at this stage. The case is presented of a patient diagnosed with uterine choriocarcinoma, whose last obstetrical event was 14 years before the current condition.</p></div><div><h3>Conclusions</h3><p>Studies of DNA microsatellite polymorphism are the most specific to confirm gestational tumour origin. Pulsatility index of the uterine artery used as a predictor of resistance to methotrexate, first-line drug in the treatment of this cancer, is currently being studied.</p></div>","PeriodicalId":41581,"journal":{"name":"Gaceta Mexicana de Oncologia","volume":"15 6","pages":"Pages 366-370"},"PeriodicalIF":0.1,"publicationDate":"2016-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.gamo.2016.09.010","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136918500","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Luis Felipe Cuéllar-Guzmán, Óscar Rafael Pérez-González
{"title":"Consideraciones perioperatorias en el paciente oncológico sometido a hepatectomía","authors":"Luis Felipe Cuéllar-Guzmán, Óscar Rafael Pérez-González","doi":"10.1016/j.gamo.2016.08.007","DOIUrl":"https://doi.org/10.1016/j.gamo.2016.08.007","url":null,"abstract":"<div><p>Hepatic cancer, either primary or secondary, is one of the most common cancer types in Mexico. Surgical procedures with palliative or therapeutic purpose have become more frequent and precise, with exponentially decreasing morbidity and mortality as procedure-related pathophysiological mechanisms become clear. Anaesthetic management of the oncological patient undergoing hepatectomy is now a diagnostic and therapeutic challenge, actively involving the anaesthesiologist in all aspects of care, from patient screening, and assessment of liver function and underlying disease related morbidities, to an active peri-operative approach, ending with the appropriate post-operative patient management. Thus, a wider review about the related diseases, their organic changes, as well as their treatment, becomes necessary.</p></div>","PeriodicalId":41581,"journal":{"name":"Gaceta Mexicana de Oncologia","volume":"15 6","pages":"Pages 358-365"},"PeriodicalIF":0.1,"publicationDate":"2016-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.gamo.2016.08.007","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136918477","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Daniel Ascencio González , Francisco Javier Ochoa Carrillo
{"title":"El secretoma de las células madre mesenquimales y la terapia celular regenerativa en cáncer","authors":"Daniel Ascencio González , Francisco Javier Ochoa Carrillo","doi":"10.1016/j.gamo.2016.11.004","DOIUrl":"https://doi.org/10.1016/j.gamo.2016.11.004","url":null,"abstract":"","PeriodicalId":41581,"journal":{"name":"Gaceta Mexicana de Oncologia","volume":"15 6","pages":"Pages 329-331"},"PeriodicalIF":0.1,"publicationDate":"2016-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.gamo.2016.11.004","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136918481","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Fernando Navarro-Tovar , Edgar Hernández-Pérez , Héctor Alejandro Carzolio-Trujillo , José Manuel Aguilar-Priego , Iván Arturo Hernández-Martínez , Jorge Miguel García-Salazar
{"title":"Hemorragia de tubo digestivo secundaria a tumor del estroma gastrointestinal localizado en yeyuno. Reporte de un caso","authors":"Fernando Navarro-Tovar , Edgar Hernández-Pérez , Héctor Alejandro Carzolio-Trujillo , José Manuel Aguilar-Priego , Iván Arturo Hernández-Martínez , Jorge Miguel García-Salazar","doi":"10.1016/j.gamo.2016.09.012","DOIUrl":"https://doi.org/10.1016/j.gamo.2016.09.012","url":null,"abstract":"<div><h3>Background</h3><p>Gastrointestinal stromal tumours (GIST) are rare, with around 20% being located in the small intestine. The most common clinical presentation is gastrointestinal bleeding, resulting from pressure necrosis and ulceration of the gastrointestinal mucosa, with laceration of the underlying vessels.</p></div><div><h3>Clinical case</h3><p>A 37-year old male, with clinical symptoms of obscure gastrointestinal bleeding. The endoscopy and colonoscopy showed no abnormalities, and an abdominal-pelvic tomography demonstrated a small bowel loop with a possible GIST being likely, due to the persistent gastrointestinal bleeding. An exploratory laparotomy it is performed, finding a tumour in the jejunum. An intestinal resection and end-to-end intestinal anastomosis was performed. With normal post-operative course, the patient was discharged on the fifth day, with histopathology reporting fusiform tumour cells and positive CD117, compatible with a stromal tumour.</p></div><div><h3>Discussion</h3><p>GISTs are derived from Cajal cells, and are characterised by mutations of c-KIT gene. They represent less than 1% of all digestive tract tumours, and occur most often in the stomach, followed by the small intestine. Its most common clinical presentation is gastrointestinal bleeding, representing 5-10% of cases when the origin is obscure. Part of surgical recommendations in the curative treatment of GIST are complete resection with negative surgical margins and pseudo-capsule (R0).</p></div><div><h3>Conclusions</h3><p>GISTs are a cause of gastrointestinal bleeding of obscure origin, with complete surgical resection being the only curative option.</p></div>","PeriodicalId":41581,"journal":{"name":"Gaceta Mexicana de Oncologia","volume":"15 6","pages":"Pages 375-380"},"PeriodicalIF":0.1,"publicationDate":"2016-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.gamo.2016.09.012","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136918498","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Francisco Javier Picó Guzmán, Raquel Andrea Hernández Gallardo, Carolina Morfin Thurmer, Esther Jeanne Marie Ruet
{"title":"Inclusión de nuevas tecnologías en los sistemas de salud públicos en México: situación regulatoria","authors":"Francisco Javier Picó Guzmán, Raquel Andrea Hernández Gallardo, Carolina Morfin Thurmer, Esther Jeanne Marie Ruet","doi":"10.1016/j.gamo.2016.09.004","DOIUrl":"https://doi.org/10.1016/j.gamo.2016.09.004","url":null,"abstract":"<div><p>One of the biggest challenges currently faced by Public Health Systems in Mexico is the decision making process about the potential inclusion of new health technologies. The aim of this work is to analyse the different tools that could help the decision-maker to optimise the benefits for the institution, as well as for the patients. This paper also focuses on the relevance of the role played by the oncologist, as an expert and advisor, in the decision making process. Finally, to fulfil the institution's requirements, it is suggested to consider the different type of uncertainties linked to the management of a public health care system in order to design innovative commercial agreements. These agreements provide access to high cost therapies without compromising the management of the institution.</p></div>","PeriodicalId":41581,"journal":{"name":"Gaceta Mexicana de Oncologia","volume":"15 5","pages":"Pages 292-297"},"PeriodicalIF":0.1,"publicationDate":"2016-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.gamo.2016.09.004","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"137339304","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Luis Tume , Carlos Cisneros , Josmell Sevillano , Romina Pacheco-Tapia , Daniel Matos , Román Acevedo-Espínola , Roberto Ubidia-Incio , Wilder Rodríguez
{"title":"Desregulación de microARN en el cáncer: un enfoque terapéutico y diagnóstico","authors":"Luis Tume , Carlos Cisneros , Josmell Sevillano , Romina Pacheco-Tapia , Daniel Matos , Román Acevedo-Espínola , Roberto Ubidia-Incio , Wilder Rodríguez","doi":"10.1016/j.gamo.2016.08.004","DOIUrl":"https://doi.org/10.1016/j.gamo.2016.08.004","url":null,"abstract":"<div><p>Cancer is one of the leading causes of death worldwide, and in many cases this is due to late detection of the disease, which complicates its treatment. MicroRNAs are short non-coding RNA sequences of ∼19-23 nucleotides that play a critical role in multiple cellular processes through post-transcriptional and translational regulation of specific genes, and an alteration in this regulatory mechanism leads to cancer. In this review, we discuss microRNA dysregulation in cancer, and propose applications of these small molecules in the treatment and diagnosis of cancer.</p></div>","PeriodicalId":41581,"journal":{"name":"Gaceta Mexicana de Oncologia","volume":"15 5","pages":"Pages 298-304"},"PeriodicalIF":0.1,"publicationDate":"2016-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.gamo.2016.08.004","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"137339309","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}